胚系DHFR与FPGS变异对甲氨蝶呤代谢及白血病复发的影响
研究在北欧儿科血液肿瘤学会ALL2008研究的447例急性淋巴细胞白血病病例中开展全基因组关联研究,并在196例独立患者中验证。位于DHFR调控区的rs1382539与短链甲氨蝶呤多聚谷氨酸水平升高相关(P=1.1×10⁻⁸),FPGS的rs35789560(p.R466C,P=5.6×10⁻⁹)与长链甲氨蝶呤多聚谷氨酸水平降低相关,且FPGS变异与复发风险增加相关(P=.044)。
要点
- DHFR调控区rs1382539与短链甲氨蝶呤多聚谷氨酸水平升高相关(P=1.1×10⁻⁸)。
- FPGS rs35789560(p.R466C)与长链甲氨蝶呤多聚谷氨酸水平降低相关(P=5.6×10⁻⁹)。
- FPGS变异与复发风险增加相关(P=.044)。
核心结论
- 这些发现表明甲氨蝶呤反应存在患者间差异的遗传基础,并可能用于改进未来的剂量算法。
研究设计与样本
- 在北欧儿科血液肿瘤学会ALL2008研究的447例急性淋巴细胞白血病病例中开展全基因组关联研究,并在196例独立患者中验证。
主要发现
- 位于DHFR调控区的rs1382539与短链甲氨蝶呤多聚谷氨酸水平升高相关(P=1.1×10⁻⁸),与增强子活性抑制相关。
- FPGS的rs35789560(p.R466C)与长链甲氨蝶呤多聚谷氨酸水平降低相关(P=5.6×10⁻⁹),通过降低催化活性实现。
- FPGS变异与复发风险增加相关(P=.044)。
关键数值与推荐
- DHFR rs1382539与短链甲氨蝶呤多聚谷氨酸水平升高相关,P=1.1×10⁻⁸。
- FPGS rs35789560(p.R466C)与长链甲氨蝶呤多聚谷氨酸水平降低相关,P=5.6×10⁻⁹。
- FPGS变异与复发风险增加相关,P=.044。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Methotrexate (MTX) during maintenance therapy is essential for curing acute lymphoblastic leukemia (ALL), but dosing strategies aiming at adequate treatment intensity are challenged by interindividual differences in drug disposition. To evaluate genetic factors associated with MTX metabolism, we performed a genome-wide association study in 447 ALL cases from the Nordic Society for Pediatric Haematology and Oncology ALL2008 study, validating results in an independent set of 196 patients. The intergenic single-nucleotide polymorphism rs1382539, located in a regulatory element of DHFR, was associated with increased levels of short-chain MTX polyglutamates (P = 1.1 × 10-8) related to suppression of enhancer activity, whereas rs35789560 in FPGS (p.R466C, P = 5.6 × 10-9) was associated with decreased levels of long-chain MTX polyglutamates through reduced catalytic activity. Furthermore, the FPGS variant was linked with increased relapse risk (P = .044). These findings show a genetic basis for interpatient variability in MTX response and could be used to improve future dosing algorithms.
引用
- Tulstrup M, Moriyama T, Jiang C, et al. Effects of germline DHFR and FPGS variants on methotrexate metabolism and relapse of leukemia. Blood. 2020. PMID: 32391884. doi:10.1182/blood.2020005064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。